Royalty Pharma (MEX:RPRX) Institutional Ownership : 44.82% (As of Dec. 16, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Royalty Pharma's institutional ownership is 44.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Royalty Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Royalty Pharma's Float Percentage Of Total Shares Outstanding is 96.23%.

Royalty Pharma Institutional Ownership Historical Data

The historical data trend for Royalty Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Institutional Ownership Chart

Royalty Pharma Historical Data

The historical data trend for Royalty Pharma can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	48.71	48.28	47.48	47.18	47.11	46.62	46.13	44.83	44.52	44.82

Royalty Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.